-
Lilly, BI diabetes drug shows greater A1C reduction in African-American adults than placebo, study shows
RIDGEFIELD, Conn. — A drug used to treat Type 2 diabetes produced significant reduction in blood sugar in African-American patients, according to results of a late-stage clinical trial.
Boehringer Ingelheim Pharmaceuticals and Eli Lilly announced Thursday results of a phase-3 trial of Tradjenta (linagliptin) in which 226 patients with Type 2 diabetes received 5 mg of the drug once per day or placebo.